Agilon Health (NYSE:AGL – Get Free Report) and COMPASS Pathways (NASDAQ:CMPS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.
Analyst Ratings
This is a summary of recent recommendations and price targets for Agilon Health and COMPASS Pathways, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Agilon Health | 2 | 12 | 4 | 0 | 2.11 |
| COMPASS Pathways | 1 | 1 | 7 | 0 | 2.67 |
Agilon Health currently has a consensus target price of $2.71, suggesting a potential upside of 272.54%. COMPASS Pathways has a consensus target price of $15.88, suggesting a potential upside of 137.65%. Given Agilon Health’s higher probable upside, equities research analysts plainly believe Agilon Health is more favorable than COMPASS Pathways.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Agilon Health | -5.24% | -75.92% | -18.35% |
| COMPASS Pathways | N/A | -111.18% | -56.55% |
Risk and Volatility
Agilon Health has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500.
Institutional & Insider Ownership
46.2% of COMPASS Pathways shares are held by institutional investors. 3.6% of Agilon Health shares are held by insiders. Comparatively, 3.9% of COMPASS Pathways shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Agilon Health and COMPASS Pathways”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Agilon Health | $6.06 billion | 0.05 | -$260.15 million | ($0.75) | -0.97 |
| COMPASS Pathways | N/A | N/A | -$155.12 million | ($2.72) | -2.46 |
COMPASS Pathways has lower revenue, but higher earnings than Agilon Health. COMPASS Pathways is trading at a lower price-to-earnings ratio than Agilon Health, indicating that it is currently the more affordable of the two stocks.
Summary
COMPASS Pathways beats Agilon Health on 7 of the 13 factors compared between the two stocks.
About Agilon Health
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.
About COMPASS Pathways
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Agilon Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilon Health and related companies with MarketBeat.com's FREE daily email newsletter.
